For instance, activating mutations in KRAS or BRAF markedly reduce the efficacy of EGFR inhibitors, illustrating the limitations of current approaches in addressing the molecular complexity of CRC [4]. The gene discussed is EGFR; the disease is colorectal carcinoma.